Ivonescimab drug page Clinical trials

Trials with Ivonescimab

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

11Trials
7Recruiting
12Countries
1.578Planned patients

Showing 1–11 of 11

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Recruiting Phase 1 370 patients NCT07397338

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RA…

United States Jan 2026 – May 2029 Interventional
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Recruiting Phase 3 600 patients NCT07228832

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…

United States, Belgium, Canada, China and 8 more Nov 2025 – Nov 2029 Interventional
Combined with: Bevacizumab
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Recruiting Phase 2 30 patients NCT07162714

Primary Objectives: Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR/MSS mid - low rectal cancer. Secondary Objectives: Evaluate treatment - r…

China Oct 2025 – Dec 2028 Interventional
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
Recruiting Phase 2 40 patients NCT06848842

The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab. The main questions it aim…

China Sept 2025 – Jun 2027 Interventional
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Recruiting Phase 2 90 patients NCT06959550

The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.

United States Jul 2025 – Jul 2030 Interventional
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
Recruiting 35 patients NCT06936488

A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer Main purpose: Evaluate the efficacy…

China Mar 2025 – Dec 2026 Interventional
Combined with: Trifluridine
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Recruiting Phase 2 45 patients NCT06802666

This study aims to evaluate the efficacy and safety of short-course radiotherapy followed by AK112 in combination with CAPOX as neoadjuvant therapy in patients with locally advanced rectal cancer

China Oct 2024 – Dec 2027 Interventional
Combined with: CapecitabineOxaliplatin
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
Not yet recruiting Phase 1 30 patients NCT07363408

This phase I trial studies the safety, side effects, and best dose of ADG126, in combination with ivonescimab alone, in combination with ivonescimab, leucovorin, and fluorouracil, or in combination with ivonescimab and leucovorin, fluorour…

United States Dec 2026 – Jul 2027 Interventional
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
Not yet recruiting Phase 2 130 patients NCT07359456

The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in terms of PF…

France Aug 2026 – Aug 2033 Interventional
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Not yet recruiting Phase 2 168 patients NCT06790212

Neoadjuvant chemotherapy has been validated by several clinical studies to achieve preoperative downstaging and improve survival outcomes in patients with locally advanced colon cancer . Enhancing the efficacy of neoadjuvant treatment furt…

Apr 2025 – Jun 2028 Interventional
Combined with: CapecitabineOxaliplatin
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
Not yet recruiting Phase 2 40 patients NCT06760520

This study is a single-arm, prospective, phase II clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with ivonescimab and chemotherapy + total mesorectal excision(TME) surgery in patients …

Jan 2025 – Dec 2031 Interventional

Where the recruiting trials are